Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Contrast Media Mol Imaging · 2018 · PMC6011117 · PMID 29977173

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.000001actually significant

As shown in Figure 3 , while reduction in binding after treatment with unlabeled DARPin 9_29 was highly significant ( p < 0.000001), there was neither significant reduction in binding after receptor saturation using trastuzumab ( p > 0.05) nor any reduction in binding after treatment of SKOV-3 cells with cetuximab or bevacizumab.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.